Restenosis prevention heart trial begins:
This article was originally published in Clinica
Executive Summary
Novoste has begun enrolling patients for a 1,100-patient trial of its Beta-Cath intracoronary beta radiation therapy device: not completed recruitment as reported in Clinica no 766, p 15. The Beta-Cath system is intended to lower the incidence of coronary restenosis, reducing the need for ongoing coronary interventions.